SEC Tracker
Get the app

SI-BONE SIBN

SI-BONE reports Q3 2026 results with 14.5% revenue growth

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Worldwide revenue of $55.7 million, up 14.5% year-over-year
  2. Net loss improved 20.7% to $3.6 million
  3. Positive adjusted EBITDA of $3.0 million
  4. Cash and equivalents of $146.3 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when SI-BONE files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Biolife Solutions BLFS public float $845M, Jun 30, 2025
  2. Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
  3. Mimedx Group MDXG public float $719M, Jun 30, 2025
  4. Heartflow HTFL
  5. Integra Lifesciences Holdings IART public float $925M, Jun 30, 2025